Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Dupilumab is prescribed for treating moderate-to-severe atopic dermatitis in adult patients who do not respond to topical treatments or cannot tolerate standard therapies. It acts as an ...

WE REPORT FOUR CASES of eyelid dermatitis in women who were patch-tested with the standard tray of 65 allergens and their own products. All four women were found to be allergic to their own ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD) have recommended oral JAK inhibitors for patients ...

Researchers compiled findings from seven studies demonstrating the real-world utility of tralokinumab for atopic dermatitis ... biologic treatments including dupilumab, abrocitinib and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting ... across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard.

The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with moderate to severe atopic dermatitis when topical treatments do not ...